Contreras T J, Lang D J, Pivacek L E, Valeri C R
Transfusion. 1979 Mar-Apr;19(2):129-36. doi: 10.1046/j.1537-2995.1979.19279160281.x.
A retrospective study of the serum of 104 patients treated at Chelsea Naval Hospital between 1969 and 1972 was done. The donor blood products were not tested for the hepatitis B antigen before transfusion. The incidence of hepatitis B antigen following transfusion was about 2.8 per cent. The incidence of antibody to HBsAg prior to transfusion was 16 per cent, and about 27 per cent of the patients developed antibody to HBsAg following transfusion. The incidence of antibody to cytomegalovirus was about 22 per cent before transfusion, and 22 per cent of the patients developed complement fixing antibody against cytomegalovirus after transfusion. Since the patients received a variety of blood products it was not possible to determine retrsopectively which product, if any, produced the lowest incidence of hepatitis B antigen and transmission of cytomegalovirus.
对1969年至1972年间在切尔西海军医院接受治疗的104名患者的血清进行了回顾性研究。所输注的供血者血液制品在输血前未检测乙肝抗原。输血后乙肝抗原的发生率约为2.8%。输血前乙肝表面抗原抗体的发生率为16%，约27%的患者在输血后产生了乙肝表面抗原抗体。输血前巨细胞病毒抗体的发生率约为22%，22%的患者在输血后产生了针对巨细胞病毒的补体结合抗体。由于患者接受了多种血液制品，因此无法回顾性地确定哪种制品（如果有的话）导致乙肝抗原的发生率和巨细胞病毒传播率最低。
